News

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...
Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...
The healthcare worker warns that most people will put two thirds of the weight back on within a year of coming off the ...
Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...
HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental ...
Those projections of reduced spending were reflected in a survey released in December by data analytics firm Numerator that ...
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...
The age-old advice to lose weight is to exercise and eat healthy, but what if you can’t work out regularly (or just don’t ...
The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...